SPOTLIGHT: King buys Avinza from Ligand

Ligand Pharmaceuticals has agreed to sell Avinza for $313 million plus royalties to King Pharmaceuticals. Approved in 2002, Avinza is a once-a-day treatment for chronic to moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time. Release